UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024
ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentation Additionally, two posters on data from the pioneering use of tape stripping for biomarker analysis […]
UNION therapeutics appoints drug development leader Dr. Peter Kristensen to its Board of Directors
Dr. Peter Kristensen, MD, DMSc, EMBA, appointed new member of UNION’s Board of Directors, bringing more than 25 years of expertise from drug development and regulatory approval from pharmaceutical companies […]
UNION therapeutics to present at 7th Annual Dermatology Drug Development Summit in Boston
Hellerup, Denmark, October 25, 2023 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. […]
UNION therapeutics announces presentation of new data on orismilast at the EADV Congress 2023
Late-breaking presentation of data from the OSIRIS IIT PoC study of oral orismilast in hidradenitis suppurativa (HS) at the European Academy of Dermatology and Venerology Congress 2023 Additional e-posters on […]
Announcement of topline results from the PROTECT-V platform study investigating niclosamide nasal spray to prevent COVID-19 infection in vaccinated but highly vulnerable patients
Hellerup, Denmark, June 16, 2023 – UNION therapeutics A/S, a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced topline results from the niclosamide arm […]
UNION therapeutics announces presentation of preliminary data on Phase 2a investigator-initiated study with orismilast at the 12th EHSF Conference and provides study update
Poster presentation of preliminary data from the Phase 2a investigator-initiated study OSIRIS at the 12th EHSF Conference Hidradenitis suppurativa (HS) is a scarring, painful, inflammatory skin disease with few or […]
First large-scale analysis confirms that vulnerable patients remain at increased fatality to COVID-19 despite availability of vaccines
Analysis includes data from UK Kidney Association (UKKA) on 9,388 COVID-19 cases among kidney patients in the UK of which 924 were fatal (Dec 2020 to March 2022) The analyses […]
UNION therapeutics announces two peer-reviewed publications of preclinical and clinical Phase 2a data on orismilast
New insights into the pharmacological properties of orismilast and Phase 2a data published in peer-reviewed journal JEADV Data supports orismilast’s potential as a first-in-class or best-in-class treatment for a range […]
UNION therapeutics to present at the Dermatology Summit 2023
UNION invited to present orismilast at the Dermatology Summit 2023 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class or best-in-class treatment for […]
UNION therapeutics and Innovent announce first subject dosed in a Chinese clinical Phase 1 study of orismilast, a novel PDE-4 inhibitor
Hellerup, Denmark and ROCKVILLE, M.D., Suzhou, China, 5 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, and Innovent […]
